ARQT vs TARS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ARQT · Arcutis Biotherapeutics$26.36 ▼ 2.98%
TARS · Tarsus Pharmaceuticals$73.01 ▼ 6.00%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ARQT -14.3%
- TARS -11.1%
Head to head
| Metric | ARQT | TARS |
|---|---|---|
| Price | $26.36 | $73.01 |
| Change today | ▼ 2.98% | ▼ 6.00% |
| Market cap | $3.33B | $3.60B |
| Return, 3 months | +6.4% | +0.3% |
| Return, year to date | -9.2% | -10.8% |
| Return, 1 year | -10.6% | -8.3% |
| P/E (TTM) | 119.8 | – |
| P/B | 13.7 | 34.6 |
| P/E percentile vs own 5y | 99th | 90th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +45.1% | +63.9% |
| Net profit growth (YoY) | +18.8% | -5,210.6% |
| Gross margin | 91.2% | 93.2% |
| Operating margin | 6.9% | -102.3% |
| Net margin | 5.9% | -102.9% |
| Return on equity | 14.9% | -319.8% |
| Analyst target vs. price | +59.3% | +44.6% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 42 | 48 |
| 30-day volatility | 90.4% | 48.8% |
| Max drawdown, 1 year | -37.5% | -32.0% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TARS is the largest of the group by market value.
- TARS has returned the most over the past year.
- TARS is growing revenue fastest.
- ARQT keeps the most profit per dollar of sales.
- TARS has been the calmest stock over the last 30 days.